Consistently, either sclerostin deficiency or the administration of sclerostin antibody protected mice from HFD-induced obesity, hyperglycemia, hyperlipidemia, insulin resistance, and fat deposition in the liver [9]. This evidence concerns the gene SOST and Hyperglycemia.